Correction to: Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy (Current Treatment Options in Oncology, (2024), 25, 3, (293-312), 10.1007/s11864-023-01173-1)

Anthony Ventu Serritella, Maha Hussain*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

Abstract

In Table 1 of this article, the value in row “CHAARTED” under the column “% Synchronous” was mistakenly listed as “Not allowed”; instead, it should be “72.8%”. In table note, the abbreviation “NA not available” should be “NA not applicable”. The original article has been corrected.

Original languageEnglish (US)
Pages (from-to)156
Number of pages1
JournalCurrent treatment options in oncology
Volume26
Issue number2
DOIs
StatePublished - Feb 2025

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Metastatic Hormone–Sensitive Prostate Cancer in the Era of Doublet and Triplet Therapy (Current Treatment Options in Oncology, (2024), 25, 3, (293-312), 10.1007/s11864-023-01173-1)'. Together they form a unique fingerprint.

Cite this